Parallax Volatility Advisers’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.1M | Buy |
+471,000
| New | +$25.6M | 0.03% | 260 |
|
|
2026
Q1 | – | Sell |
-261,500
| Closed | -$24.9M | – | 1493 |
|
|
2025
Q4 | $24.9M | Buy |
+261,500
| New | +$25.6M | 0.05% | 256 |
|
|
2025
Q1 | – | Sell |
-52,700
| Closed | -$4.71M | – | 1616 |
|
|
2024
Q4 | $4.71M | Hold |
52,700
| – | – | 0.01% | 845 |
|
|
2024
Q3 | $4.42M | Buy |
52,700
+42,800
| +432% | +$3.37M | 0.01% | 845 |
|
|
2024
Q2 | $762K | Buy |
9,900
+1,100
| +13% | +$80.5K | ﹤0.01% | 1333 |
|
|
2024
Q1 | $603K | Sell |
8,800
-274,600
| -97% | -$17.7M | ﹤0.01% | 1353 |
|
|
2023
Q4 | $16.4M | Buy |
283,400
+59,800
| +27% | +$3.19M | 0.03% | 447 |
|
|
2023
Q3 | $11.8M | Buy |
223,600
+29,300
| +15% | +$1.54M | 0.03% | 491 |
|
|
2023
Q2 | $10.5M | Sell |
194,300
-7,900
| -4% | -$413K | 0.02% | 517 |
|
|
2023
Q1 | $10.1M | Sell |
202,200
-62,800
| -24% | -$2.96M | 0.02% | 582 |
|
|
2022
Q4 | $12.3M | Buy |
265,000
+110,500
| +72% | +$4.78M | 0.02% | 707 |
|
|
2022
Q3 | $5.98M | Buy |
154,500
+74,700
| +94% | +$3M | 0.01% | 941 |
|
|
2022
Q2 | $2.97M | Sell |
79,800
-34,500
| -30% | -$1.4M | ﹤0.01% | 1186 |
|
|
2022
Q1 | $5.06M | Sell |
114,300
-135,500
| -54% | -$5.87M | ﹤0.01% | 981 |
|
|
2021
Q4 | $10.6M | Sell |
249,800
-64,300
| -20% | -$2.7M | 0.01% | 868 |
|
|
2021
Q3 | $13.6M | Buy |
314,100
+206,900
| +193% | +$9.15M | 0.01% | 803 |
|
|
2021
Q2 | $4.58M | Buy |
107,200
+68,600
| +178% | +$2.89M | ﹤0.01% | 1274 |
|
|
2021
Q1 | $1.49M | Sell |
38,600
-566,400
| -94% | -$21.4M | ﹤0.01% | 1887 |
|
|
2020
Q4 | $21.8M | Sell |
605,000
-454,900
| -43% | -$16.4M | 0.02% | 732 |
|
|
2020
Q3 | $40.5M | Sell |
1,059,900
-55,500
| -5% | -$2.14M | 0.03% | 465 |
|
|
2020
Q2 | $39.2M | Buy |
1,115,400
+292,200
| +35% | +$10.5M | 0.05% | 320 |
|
|
2020
Q1 | $26.9M | Buy |
823,200
+730,600
| +789% | +$28.5M | 0.03% | 340 |
|
|
2019
Q4 | $4.19M | Sell |
92,600
-32,800
| -26% | -$1.37M | ﹤0.01% | 970 |
|
|
2019
Q3 | $5.1M | Sell |
125,400
-89,400
| -42% | -$3.79M | 0.01% | 807 |
|
|
2019
Q2 | $9.23M | Buy |
214,800
+144,400
| +205% | +$5.55M | 0.01% | 542 |
|
|
2019
Q1 | $2.71M | Buy |
70,400
+200
| +0.3% | +$7.64K | ﹤0.01% | 895 |
|
|
2018
Q4 | $2.48M | Buy |
70,200
+54,400
| +344% | +$1.97M | ﹤0.01% | 974 |
|
|
2018
Q3 | $608K | Buy |
+15,800
| New | +$552K | ﹤0.01% | 1392 |
|
|
2017
Q1 | – | Sell |
-22,600
| Closed | -$489K | – | 3579 |
|
|
2016
Q4 | $489K | Buy |
+22,600
| New | +$493K | ﹤0.01% | 1516 |
|
|
2015
Q2 | – | Sell |
-24,600
| Closed | -$437K | – | 3645 |
|
|
2015
Q1 | $437K | Sell |
24,600
-540,000
| -96% | -$8.53M | ﹤0.01% | 1621 |
|
|
2014
Q4 | $7.48M | Buy |
+564,600
| New | +$7.22M | 0.02% | 559 |
|
Other funds holding BSX
Parallax Volatility Advisers's BSX Position: Q2 2026 in Review
Parallax Volatility Advisers increased its Boston Scientific (BSX) stake by 9,634% in Q2 2026, buying an estimated $7.27M and bringing the position to 135,199 shares worth $5.77M. The position accounts for 0.01% of the portfolio, ranked #558.
Parallax Volatility Advisers first reported a position in BSX in Q4 2014 and has held it in 32 quarters since. The position peaked at $19.2M in Q1 2020. 1,481 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Parallax Volatility Advisers held 135,199 shares of Boston Scientific worth $5.77M as of Q2 2026.
- Parallax Volatility Advisers bought 133,810 Boston Scientific shares in Q2 2026, an estimated $7.27M.
- Boston Scientific made up 0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #558 holding.
- Parallax Volatility Advisers first reported a position in Boston Scientific in Q4 2014 and has held it in 32 quarters since.
- Parallax Volatility Advisers's Boston Scientific position peaked at $19.2M in Q1 2020.
- 1,481 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.